Affiliation:
1. The author is in the Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.
Abstract
The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery—such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.
Publisher
American Association for the Advancement of Science (AAAS)
Reference39 articles.
1. Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
2. Davis K. L., et al., N. Engl. J. Med. 237, 1253 (1992);
3. Rogers S. L., Doody R. S., Mohs R. C., Friedhoff L. T., Arch. Int. Med. 158, 1021 (1998) .
4. H. Braak and E. Braak in Neurodegenerative Diseases D. B. Calne Ed. (Saunders Philadelphia 1994) pp. 585–613.
5. Cotzias G. C., VanWoert M. H., Schiffer L. M., N. Engl. J. Med. 276, 374 (1967);
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献